File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s13669-013-0071-6
- PMID: 24533232
- WOS: WOS:000218712800010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease
Title | Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease |
---|---|
Authors | |
Issue Date | 2014 |
Publisher | Springer Healthcare. |
Citation | Current Obstetrics and Gynecology Reports, 2014, v. 3 n. 1, p. 84-90 How to Cite? |
Abstract | Gestational trophoblastic neoplasia (GTN) is highly chemosensitive and has a high cure rate. Since the introduction of chemotherapy, reliable measurement of human chorionic gonadotropin (hCG) levels, and individualised risk-based therapy into the management of GTN, almost all low-risk and more than 80 % of high-risk GTN cases are curable. However, approximately 25 % of high-risk GTN developed resistance to chemotherapy or relapsed after completion of initial therapy, which often necessitate salvage combination chemotherapy. On the other end of the spectrum, a proportion of patients with gestational trophoblastic disease (GTD) have persistently low levels of hCG, without clinical or radiological evidence of disease, a condition called quiescent GTD. Recently, measurement of hyperglycosylated hCG has been proposed for the management of patients with quiescent GTD. Although representing a small proportion of GTD cases, the management of patients with chemoresistant and quiescent GTD often poses challenges to medical practitioners. |
Persistent Identifier | http://hdl.handle.net/10722/193928 |
ISSN | 2019 SCImago Journal Rankings: 0.114 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ngu, SF | en_US |
dc.contributor.author | Chan, KKL | en_US |
dc.date.accessioned | 2014-01-28T06:34:31Z | - |
dc.date.available | 2014-01-28T06:34:31Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Current Obstetrics and Gynecology Reports, 2014, v. 3 n. 1, p. 84-90 | en_US |
dc.identifier.issn | 2161-3303 | - |
dc.identifier.uri | http://hdl.handle.net/10722/193928 | - |
dc.description.abstract | Gestational trophoblastic neoplasia (GTN) is highly chemosensitive and has a high cure rate. Since the introduction of chemotherapy, reliable measurement of human chorionic gonadotropin (hCG) levels, and individualised risk-based therapy into the management of GTN, almost all low-risk and more than 80 % of high-risk GTN cases are curable. However, approximately 25 % of high-risk GTN developed resistance to chemotherapy or relapsed after completion of initial therapy, which often necessitate salvage combination chemotherapy. On the other end of the spectrum, a proportion of patients with gestational trophoblastic disease (GTD) have persistently low levels of hCG, without clinical or radiological evidence of disease, a condition called quiescent GTD. Recently, measurement of hyperglycosylated hCG has been proposed for the management of patients with quiescent GTD. Although representing a small proportion of GTD cases, the management of patients with chemoresistant and quiescent GTD often poses challenges to medical practitioners. | en_US |
dc.language | eng | en_US |
dc.publisher | Springer Healthcare. | - |
dc.relation.ispartof | Current Obstetrics and Gynecology Reports | en_US |
dc.title | Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease | en_US |
dc.type | Article | en_US |
dc.identifier.email | Ngu, SF: ngusiewf@hku.hk | en_US |
dc.identifier.email | Chan, KKL: kklchan@hkucc.hku.hk | en_US |
dc.identifier.authority | Ngu, SF=rp01367 | en_US |
dc.identifier.authority | Chan, KKL=rp00499 | en_US |
dc.identifier.doi | 10.1007/s13669-013-0071-6 | - |
dc.identifier.pmid | 24533232 | - |
dc.identifier.pmcid | PMC3920061 | - |
dc.identifier.hkuros | 227449 | en_US |
dc.identifier.volume | 3 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 84 | - |
dc.identifier.epage | 90 | - |
dc.identifier.isi | WOS:000218712800010 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 2161-3303 | - |